The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Developed by the Sudha Gopalakrishnan Brain Centre, the publicly accessible ANCHOR atlas maps over 200 brainstem structures at cellular resolution, offering new possibilities for neuroscience research and clinical applications
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Baxfendy works in a fundamentally different way from current therapies
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
